Difference between revisions of "Vismodegib (Erivedge)"
m |
(updated content) |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Hedgehog pathway inhibitor. Vismodegib binds to and inhibits the transmembrane protein Smoothened (SMO), which is part of the Hedgehog signal transduction pathway that is clinically relevant in diseases such as basal cell cancer.<ref name="insert">[http://www.gene.com/gene/products/information/erivedge/pdf/erivedge_prescribing.pdf Vismodegib (Erivedge) package insert]</ref><ref>[ | + | Class/mechanism: Hedgehog pathway inhibitor. Vismodegib binds to and inhibits the transmembrane protein Smoothened (SMO), which is part of the Hedgehog signal transduction pathway that is clinically relevant in diseases such as basal cell cancer.<ref name="insert">[http://www.gene.com/gene/products/information/erivedge/pdf/erivedge_prescribing.pdf Vismodegib (Erivedge) package insert]</ref><ref>[[Media:Vismodegib.pdf | Vismodegib (Erivedge) package insert (locally hosted backup)]]</ref><ref>[http://www.erivedge.com/ Erivedge manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 12: | Line 10: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://www.erivedge.com/patient/ | + | *[http://www.erivedge.com/patient/side-effects/side-effect-tips.html Erivedge manufacturer side effect tips]<ref>[http://www.erivedge.com/patient/side-effects/side-effect-tips.html Erivedge manufacturer side effect tips]</ref> |
| + | *[http://www.uptodate.com/contents/vismodegib-drug-information Vismodegib (Erivedge) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vismodegib-drug-information Vismodegib (Erivedge) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
Revision as of 08:34, 2 March 2015
General information
Class/mechanism: Hedgehog pathway inhibitor. Vismodegib binds to and inhibits the transmembrane protein Smoothened (SMO), which is part of the Hedgehog signal transduction pathway that is clinically relevant in diseases such as basal cell cancer.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Erivedge manufacturer side effect tips[4]
- Vismodegib (Erivedge) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1/30/2012: Initial FDA approval "for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation."
Also known as
Hedgehog antagonist GDC-0449, GDC-0449, Erivedge